126 related articles for article (PubMed ID: 34886801)
1. Higher body mass index indicated better overall survival in pancreatic ductal adenocarcinoma patients: a real-world study of 2010 patients.
Fu N; Jiang Y; Qin K; Chen H; Deng X; Shen B
BMC Cancer; 2021 Dec; 21(1):1318. PubMed ID: 34886801
[TBL] [Abstract][Full Text] [Related]
2. Body mass index does not affect the survival of pancreatic cancer patients.
Jiang QL; Wang CF; Tian YT; Huang H; Zhang SS; Zhao DB; Ma J; Yuan W; Sun YM; Che X; Zhang JW; Chu YM; Zhang YW; Chen YT
World J Gastroenterol; 2017 Sep; 23(34):6287-6293. PubMed ID: 28974895
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer.
Bagni K; Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Hansen CP; Preus Hasselby J; Holländer NH; Nissen M; Bjerregaard JK; Pfeiffer P; Yilmaz MK; Rasmussen LS; Nielsen SE; Johansen JS
Eur J Cancer Care (Engl); 2020 May; 29(3):e13219. PubMed ID: 31908093
[TBL] [Abstract][Full Text] [Related]
4. Who could complete and benefit from the adjuvant chemotherapy regarding pancreatic ductal adenocarcinoma? A multivariate-adjusted analysis at the pre-adjuvant chemotherapy timing.
Fu N; Qin K; Li J; Jin J; Jiang Y; Deng X; Shen B
Cancer Med; 2022 Sep; 11(18):3397-3406. PubMed ID: 35434972
[TBL] [Abstract][Full Text] [Related]
5. Body mass index and pancreatic adenocarcinoma: A nationwide registry-based cohort study.
Saeed U; Myklebust TÅ; Robsahm TE; Møller B; Mala T; Skålhegg BS; Yaqub S
Scand J Surg; 2023 Mar; 112(1):11-21. PubMed ID: 36173093
[TBL] [Abstract][Full Text] [Related]
6. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
[TBL] [Abstract][Full Text] [Related]
7. Prognostic relevance of lactate dehydrogenase in advanced pancreatic ductal adenocarcinoma patients.
Xiao Y; Chen W; Xie Z; Shao Z; Xie H; Qin G; Zhao N
BMC Cancer; 2017 Jan; 17(1):25. PubMed ID: 28056913
[TBL] [Abstract][Full Text] [Related]
8. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis.
Zhang K; Dong S; Jing YH; Gao HF; Chen LY; Hua YQ; Chen H; Chen Z
BMC Cancer; 2020 Jun; 20(1):541. PubMed ID: 32517802
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study.
Ninomiya G; Fujii T; Yamada S; Yabusaki N; Suzuki K; Iwata N; Kanda M; Hayashi M; Tanaka C; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Int J Surg; 2017 Mar; 39():45-51. PubMed ID: 28110029
[TBL] [Abstract][Full Text] [Related]
10. Reduced mean platelet volume levels predict shorter survival in patients with resectable pancreatic ductal adenocarcinoma and type 2 diabetes.
Yin JB; Li N; Cui MM; Wang X; Wang RT
BMC Gastroenterol; 2020 May; 20(1):143. PubMed ID: 32393273
[TBL] [Abstract][Full Text] [Related]
11. Body Mass Index Trajectories Across the Adult Life Course and Pancreatic Cancer Risk.
Arjani S; Saint-Maurice PF; Julián-Serrano S; Eibl G; Stolzenberg-Solomon R
JNCI Cancer Spectr; 2022 Nov; 6(6):. PubMed ID: 36255251
[TBL] [Abstract][Full Text] [Related]
12. Risk Factors in Pancreatic Adenocarcinoma: the Interrelation with Familial History and Predictive Role on Survival.
Petrusel L; Bilibou M; Drug V; Leucuta DC; Seicean R; Cainap C; Seicean A
J Gastrointestin Liver Dis; 2020 Sep; 29(3):391-398. PubMed ID: 32919422
[TBL] [Abstract][Full Text] [Related]
13. The Main Bottleneck for Non-Metastatic Pancreatic Adenocarcinoma in Past Decades: A Population-Based Analysis.
Li Y; Liu W; Zhao L; Xu Y; Yan T; Yang Q; Pei Q; Güngör C
Med Sci Monit; 2020 May; 26():e921515. PubMed ID: 32358953
[TBL] [Abstract][Full Text] [Related]
14. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
Amin S; Baine M; Meza J; Lin C
BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
[TBL] [Abstract][Full Text] [Related]
15. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
[TBL] [Abstract][Full Text] [Related]
17. Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe.
Javed MA; Beyer G; Le N; Vinci A; Wong H; Palmer D; Morgan RD; Lamarca A; Hubner RA; Valle JW; Alam S; Chowdhury S; Ma YT; Archibugi L; Capurso G; Maisonneuve P; Neesse A; Sund M; Schober M; Krug S
Pancreatology; 2019 Jan; 19(1):97-104. PubMed ID: 30529068
[TBL] [Abstract][Full Text] [Related]
18. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection.
Ilmer M; Schiergens TS; Renz BW; Schneider C; Sargut M; Waligora R; Weniger M; Hartwig W; Ceyhan GO; Friess H; Werner J; D'Haese JG
Surg Oncol; 2019 Dec; 31():16-21. PubMed ID: 31473583
[TBL] [Abstract][Full Text] [Related]
19. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
20. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
